Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone

Table 4 Predicted survival, events and costs by treatment group and time horizon

Treatment group	Time horizon (years)	Survival rates (%)	Number of events in a hypothetical population of 5000 subjects								Average cumulative costs of complications per patient (US$- discounted)
			CVD	MI	Stroke	CHF	Renal disorders (including ESRD death)*	Visual disorders†	Amputation (first and recurrent)
			N (%)
Liraglutide 1.2 mg	10	82.4	727	14.54%	346	140	381	621	1261	144	14,126.53
	20	49.0	2,049	40.98%	900	381	992	1322	2534	384	29,850.63
	30	15.0	3,484	69.68%	1373	563	1476	1756	3242	565	38,963.07
Liraglutide 1.8 mg	10	82.3	728	14.56%	355	160	391	622	1271	115	14,162.06
	20	49.2	2,017	40.34%	881	421	987	1296	2578	358	30,021.86
	30	16.0	3,419	68.38%	1323	611	1478	1695	3233	529	39,239.92
Rosiglitazone 4 mg	10	80.8	782	15.64%	444	161	422	804	1548	113	15,237.10
	20	45.5	2,227	44.54%	1062	385	1060	1541	2910	347	31,243.92
	30	12.6	3,624	72.48%	1574	586	1489	1923	3529	507	40,401.96

*Microalbuminuria + Gross proteinuria + ESRD + ESRD death.
^†Background retinopathy + proliferative retinopathy + macular edema + severe vision loss + Cataract.
CHF, congestive heart failure; CVD, cardiovascular death; ESRD, end-stage renal disease MI, myocardial infarction.

ISSN: 1475-2840